Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis-Reference-Cited by-同舟云学术

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis

Published:2016-08-26 Issue:1 Volume:13 Page:
ISSN:1742-2094
Container-title:Journal of Neuroinflammation
language:en
Short-container-title:J Neuroinflammation

Author:

Gentile Antonietta,Musella Alessandra,Bullitta Silvia,Fresegna Diego,De Vito Francesca,Fantozzi Roberta,Piras Eleonora,Gargano Francesca,Borsellino Giovanna,Battistini Luca,Schubart Anna,Mandolesi Georgia,Centonze Diego

Funder

Novartis Pharma

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology,Immunology,General Neuroscience

Link

http://link.springer.com/content/pdf/10.1186/s12974-016-0686-4

Reference54 articles.

1. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.

2. Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJ, Reynolds R, Martin R. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci. 2015;16:147–58.

3. Salvetti M, Landsman D, Schwarz-Lam P, Comi G, Thompson AJ, Fox RJ. Progressive MS: from pathophysiology to drug discovery. Mult Scler. 2015;21:1376–84.

4. Fyfe I. In the news: ocrelizumab excites ECTRIMS. Nat Rev Neurol. 2015;11:667.

5. Ciccarelli O, Barkhof F, Bodini B, De Stefano N, Golay X, Nicolay K, et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014;13:807–22.

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contribution of microglia/macrophage to the pathogenesis of TMEV infection in the central nervous system;Frontiers in Microbiology;2024-08-02

2. Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models;Scientific Reports;2024-08-01

3. How does Nogo-A signalling influence mitochondrial function during multiple sclerosis pathogenesis?;Neuroscience & Biobehavioral Reviews;2024-08

4. Pharmacological blockade of 2-AG degradation ameliorates clinical, neuroinflammatory and synaptic alterations in experimental autoimmune encephalomyelitis;Neuropharmacology;2024-07

5. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis;Frontiers in Immunology;2024-06-07